University of Pittsburgh Medical Center: Trastuzumab Emtansine Improves Overall Survival in HER2 Breast Cancer
January 16, 2025
January 16, 2025
PITTSBURGH, Pennsylvania, Jan. 16 (TNSjou) -- The University of Pittsburgh Medical Center issued the following news release:
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pitts . . .
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pitts . . .